Public Health Science Explainer

Phage therapy
a living medicine

For a century, antibiotics were medicine's greatest weapon. But as resistance spreads, scientists are rediscovering something older — a therapy that uses nature's own assassins to kill bacteria with surgical precision.

Read the story

What is phage therapy, exactly?

Phage therapy is the use of bacteriophages — viruses that infect and destroy bacteria — as a medical treatment. Rather than using a chemical drug, phage therapy deploys a living biological agent that seeks out specific bacteria and kills them from within.

The concept is not new. Georgian and French scientists were using phages therapeutically as far back as the 1920s, predating the widespread use of antibiotics. But the discovery of penicillin effectively sidelined the research — particularly in the West — for the better part of a century. Today, faced with a global antibiotic resistance crisis, that research is experiencing a significant revival.

🔬

How it works — step by step

A phage lands on a bacterium and injects its genetic material into it. The bacterium's own cellular machinery is hijacked to produce hundreds of new phage copies. Those copies burst out of the bacterium — killing it in the process — and go on to infect neighbouring bacteria. The process repeats until the bacterial population collapses. Crucially, phages can only infect bacteria, never human cells.

1920s
phage therapy first used clinically in humans
10³¹
estimated phages on Earth — more than every other life form combined
<24h
typical time to identify and match phages to a target bacterium

Eight reasons phage therapy matters

Phage therapy is not simply a substitute for antibiotics — it is a fundamentally different approach with a distinct and often complementary set of advantages.

🎯

Precision targeting

Each phage strain targets one specific species — sometimes one specific strain — of bacteria. Beneficial microbiome bacteria are left entirely unharmed. Antibiotics offer no such selectivity.

🔄

Self-amplifying treatment

Unlike drugs that dilute over time, phages multiply at the site of infection. The treatment intensifies exactly where it is needed and fades naturally when bacteria are gone.

🧬

Co-evolution with bacteria

Phages can evolve alongside resistant bacteria. Researchers can select phages that counter specific resistance mechanisms — an adaptability no chemical antibiotic can match.

🏥

Effective against biofilms

Chronic infections often hide inside bacterial biofilms — sticky protective layers that are notoriously impenetrable to antibiotics. Certain phages carry enzymes that dissolve these biofilms.

⚗️

Synergy with antibiotics

Phages and antibiotics can work together. In several studies, combining the two achieved results neither achieved alone — opening the door to lower antibiotic doses and reduced side effects.

🌿

Minimal collateral damage

Antibiotics can cause allergic reactions, gut dysbiosis, and systemic side effects. Phages, being highly specific, cause none of these. The gut microbiome remains intact.

⚡

Rapid development

A new phage preparation targeting a specific bacterium can be identified and prepared in days. Developing a new antibiotic takes a decade or more and costs billions of pounds.

♻️

Reduced resistance pressure

Because phages target bacteria so specifically and co-evolve with them, they impose far less selection pressure for broad antibiotic resistance — helping slow the global resistance crisis.

"Phages have been killing bacteria for three billion years without a single patent application. We are only beginning to understand how to put that expertise to medical use."

Phage therapy vs antibiotics

Phage therapy and antibiotics each have genuine strengths. Understanding the differences is essential to knowing when each approach is most appropriate — and why combining them may prove to be the most powerful strategy of all.

Property Phage Therapy Antibiotics
Spectrum of action
✓ Highly specific — one phage, one species
Broad — kills many species, including beneficial bacteria
Effect on microbiome
✓ Microbiome preserved entirely
✗ Often causes significant dysbiosis
Resistance risk
✓ Can co-evolve; resistance often costly to bacteria
✗ Resistance spreads rapidly and widely
Biofilm penetration
✓ Specialist phages dissolve biofilms
✗ Largely ineffective against established biofilms
Side effects
✓ Minimal — no systemic toxicity
✗ Allergic reactions, GI effects, organ toxicity
Development speed
✓ Days to identify a new phage preparation
✗ 10–15 years to develop and approve a new drug
Self-amplification
✓ Multiplies at infection site
No — concentration dilutes over time
Regulatory status
Still emerging — frameworks developing
✓ Fully established globally
Evidence base
Growing fast — large trials underway
✓ Decades of large-scale clinical data
Manufacturing scale
Technically demanding at scale
✓ Well-established industrial production
⚔️
Not rivals — partners

The most promising direction is not phage therapy replacing antibiotics, but the two working together. Phages can be used to reduce bacterial load and break down biofilms, making the remaining bacteria vulnerable to lower, safer doses of antibiotics. The combination has shown results in cases that neither approach could resolve alone.

Clinical applications showing the most promise

Phage therapy is not a single treatment for a single condition. It is a flexible platform with applications across many of medicine's most difficult infection challenges.

🦴

Bone & joint infections

Prosthetic joint infections are notoriously resistant to treatment. Phage therapy combined with surgery and antibiotics has resolved cases that had failed all other approaches.

🫁

Cystic fibrosis lung infections

Pseudomonas aeruginosa and other pathogens chronically infect CF patients' lungs. Inhaled phage therapy is being tested to reduce bacterial burden without damaging the airway microbiome.

💉

Bloodstream infections

Bacteraemia — bacteria in the blood — can be fatal within hours. Phage therapy delivered intravenously has been used in emergency compassionate-use cases with remarkable outcomes.

🩹

Wound & skin infections

Chronic wounds colonised by drug-resistant organisms are increasingly treated with phage-impregnated dressings, offering targeted bacterial clearance without systemic drugs.

🚽

Urinary tract infections

Recurrent UTIs, often caused by E. coli or Klebsiella resistant to standard antibiotics, are among the leading targets for phage therapy trials currently recruiting patients.

🏨

Hospital-acquired infections

ICU patients are disproportionately affected by ESKAPE pathogens. Phage therapy represents a potentially transformative tool for infections that currently carry very high mortality.

From discovery to 21st-century revival

Phage therapy has a longer history than most people realise — and its modern revival is accelerating rapidly, driven by the global antimicrobial resistance crisis.

1915 – 1917
Discovery of bacteriophages
Frederick Twort and Félix d'Hérelle independently discover agents that destroy bacteria. D'Hérelle coins the term "bacteriophage" and immediately envisions therapeutic applications.
1920s – 1940s
First clinical use
Phage preparations are used to treat dysentery, cholera, and wound infections. The Eliava Institute in Georgia (USSR) becomes a world centre for phage therapy research — a role it maintains to this day.
1940s – 1980s
Overshadowed by antibiotics
The discovery of penicillin and subsequent antibiotics dominates Western medicine. Phage research continues behind the Iron Curtain but largely disappears from Western scientific literature.
2006
First FDA regulatory approval
A phage preparation is approved by the US FDA for use as a food safety spray to combat Listeria — the first formal regulatory recognition of phage therapy in the West.
2016 – present
High-profile compassionate-use successes
Several landmark cases — including the life-saving phage treatment of a patient with a drug-resistant Acinetobacter infection at UC San Diego — attract major scientific and public attention. Clinical trials multiply worldwide.
2024 – 2026
The clinical trial era begins in earnest
Multiple phase II and phase III trials are underway across Europe, North America, and Australia. Regulatory frameworks are actively being developed. The field is transitioning from pioneering cases to systematic evidence.

What still needs to be solved

Phage therapy's promise is real and backed by growing evidence. But honest science requires acknowledging the genuine obstacles that remain before it becomes a routine medical tool.

Current challenges

Finding the right phage for a specific infection requires rapid diagnostic capacity not yet widely available in clinical settings. The immune system can sometimes produce antibodies against phages, potentially reducing efficacy on repeat treatment. Because phages are so strain-specific, a single preparation may not cover all variants of a pathogen circulating in a given region. Regulatory agencies around the world are still developing approval pathways — making access inconsistent. Manufacturing phages to the purity and consistency required for medicine at large scale remains technically complex. None of these barriers are insurmountable, and each is the subject of active research.

🔭
Where the field is heading

Several strategies are emerging to address these challenges: engineered "broad-spectrum" phage cocktails that cover multiple strains; phage banks that can be rapidly screened against any new pathogen; and synthetic biology approaches that let scientists design phages with tailored properties from scratch. The tools are advancing quickly.

Living medicine for
a resistant world

Antibiotics transformed medicine in the twentieth century. But their era of unchallenged dominance is ending — not because they have failed, but because bacteria have adapted faster than our chemistry can keep pace.

Phage therapy does not ask bacteria to stand still. It evolves alongside them. It works with the logic of biology rather than against it, and it offers a level of precision that chemistry may never achieve.

We are still in the early chapters of this story. But after a century of detour, the most abundant predator on Earth is finally getting the clinical attention it deserves.